Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study
Michele Guida, Sabino Strippoli, Milena Maule, et al.
ESMO Open (2021) Vol. 6, Iss. 2, pp. 100064-100064
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Immune-checkpoint inhibitors: long-term implications of toxicity
Douglas B. Johnson, Caroline A. Nebhan, Javid J. Moslehi, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 4, pp. 254-267
Open Access | Times Cited: 644
Cutaneous manifestations associated with immune checkpoint inhibitors
Tomoya Watanabe, Yukie Yamaguchi
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 44
Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article
Chieh‐Hsun Chen, Hsin‐Su Yu, Sebastian Yu
Current Oncology (2022) Vol. 29, Iss. 4, pp. 2871-2886
Open Access | Times Cited: 40
Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors
Yi-Shan Teng, Sebastian Yu
Current Oncology (2023) Vol. 30, Iss. 7, pp. 6805-6819
Open Access | Times Cited: 22
A deep learning model based on whole slide images to predict disease-free survival in cutaneous melanoma patients
Maria Colomba Comes, Livia Fucci, F. Mele, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 23
On-Target Side Effects of Targeted Therapeutics of Cancer
József Tı́már, Andrea Uhlyarik
Pathology & Oncology Research (2022) Vol. 28
Open Access | Times Cited: 22
Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update
Kylie Fletcher, Douglas B. Johnson
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 7, pp. e008591-e008591
Open Access | Times Cited: 4
Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital
Gloria Juan‐Carpena, Natividad Martínez-Banaclocha, Juan Carlos Palazón Cabanes, et al.
Acta Dermato Venereologica (2025) Vol. 105, pp. adv42023-adv42023
Open Access
Monocyte-related markers as predictors of immune checkpoint inhibitor efficacy and immune-related adverse events: a systematic review and meta-analysis
Aiarpi Ezdoglian, M. Tsang-A-Sjoe, Fatemeh Khodadust, et al.
Cancer and Metastasis Reviews (2025) Vol. 44, Iss. 1
Open Access
Case report: Is severe toxicity the price to pay for high sensitivity to checkpoint inhibitors immunotherapy in desmoplastic melanoma?
Teresa Squicciarini, Rossella Villani, Benedetta Apollonio, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
The many faces of autoimmune-mediated melanocyte destruction in melanoma
Loredana Ungureanu, Alina Vasilovici, Salomea-Ruth Halmágyi, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Quiescence and aging of melanocyte stem cells and a novel association with PD-L1
Joseph W. Palmer, Kyrene M. Villavicencio, Misgana I. Idris, et al.
iScience (2024) Vol. 27, Iss. 10, pp. 110908-110908
Open Access | Times Cited: 1
Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records
Mathilde Beaufils, Vincent Amodru, Manuel Tejeda, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 8, pp. e006786-e006786
Open Access | Times Cited: 4
Cutaneous immune-related adverse events: incidence rates, risk factors and association with extracutaneous toxicity – a prospective study of 189 patients treated with checkpoint inhibitors at a Spanish tertiary care hospital
Gloria Juan‐Carpena, Natividad Martínez-Banaclocha, Juan Carlos Palazón‐Cabanes, et al.
Clinical and Experimental Dermatology (2024) Vol. 49, Iss. 9, pp. 991-1001
Closed Access | Times Cited: 1
Clinical Presentation and Prognostic Features in Patients with Immunotherapy-Induced Vitiligo-like Depigmentation: A Monocentric Prospective Observational Study
Nicola Hermann, Lara Valeska Maul, Milad Ameri, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4576-4576
Open Access | Times Cited: 7
Widespread vitiligo and poliosis following ipilimumab–nivolumab combination therapy
Khashayar Nemovi, Arsia Jamali, Keyan Matinpour, et al.
Journal of Oncology Pharmacy Practice (2023) Vol. 29, Iss. 5, pp. 1278-1282
Closed Access | Times Cited: 3
Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the Scalp
Davide Quaresmini, Alessandra Di Lauro, Livia Fucci, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 8
The Benefits and Challenges of the Multimodal Treatment in Advanced/Metastatic Malignant Melanoma
Alexandru-Rares Stoian, G. Nita, Anda-Natalia Ciuhu, et al.
Diagnostics (2023) Vol. 13, Iss. 9, pp. 1635-1635
Open Access | Times Cited: 2
Vitiligo-like hypopigmentation induced by dabrafenib-trametinib: a potential marker for clinical response
Elena Carmona‐Rocha, Ivana Sullivan, Oriol Yélamos
Melanoma Research (2023) Vol. 33, Iss. 6, pp. 553-555
Closed Access | Times Cited: 2
[Translated article] Characteristics, Management, and Prognostic Implications of Adverse Effects of Immune Checkpoint Inhibitors: A Systematic Review
Gloria Juan‐Carpena, Juan Carlos Palazón‐Cabanes, Mar Blanes‐Martínez
Actas Dermo-Sifiliográficas (2022) Vol. 113, Iss. 4, pp. T376-T387
Open Access | Times Cited: 4
Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients
Sofia Verkhovskaia, Francesca Romana Di Pietro, Simona Mastroeni, et al.
Journal of Cancer Research and Clinical Oncology (2021) Vol. 148, Iss. 9, pp. 2529-2538
Open Access | Times Cited: 5
Revisión sistemática de los efectos adversos cutáneos causados por fármacos inhibidores de los puntos de control inmunitario: características, manejo y pronóstico
Gloria Juan‐Carpena, J.C. Palazón-Cabanes, Mar Blanes‐Martínez
Actas Dermo-Sifiliográficas (2021) Vol. 113, Iss. 4, pp. 376-387
Open Access | Times Cited: 5
The relationship between PD-L1 and quiescence in melanocyte stem cell aging
Joseph W. Palmer, Kyrene M. Villavicencio, Misgana I. Idris, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 3
Alectinib induced vitiligo with rapid re-pigmentation
Meng Wang, Tianyu Wang, Jiao Shan, et al.
European Journal of Cancer (2024) Vol. 200, pp. 113582-113582
Closed Access
Monocyte-Related Markers as Predictors of Immune Checkpoint Inhibitor Efficacy and Immune-Related Adverse Events: A Systematic Review and Meta-Analysis
Aiarpi Ezdoglian, M. Tsang-A-Sjoe, Fatemeh Khodadust, et al.
(2024)
Closed Access
Page 1 - Next Page

Scroll to top